Poseida Therapeutics Poseida Therapeutics Provides Update on Phase 1 Study of P-BCMA-101 CAR-T Product Candidate at the 2018 American Society of Hematology Annual Meeting P-BCMA-101 showed a 100% ORR with…
Read More
Read news items items specific to Ponce Therapeutics or about other Rapha Capital-related entities. Also see scientific articles detailing the rapid advances in the important science of anti-aging
News
Bellicum Pharmaceuticals, Inc. Bellicum Announces Data Presentation at ASH 2018 Demonstrating Low Rates of Cancer Recurrence in Pediatric AML and ALL Patients Treated with Rivo-cel Results show high rates of…
Bellicum Pharmaceuticals, Inc. Bellicum Announces Favorable Interim Event-Free Survival Data for Rivo-cel Treated Patients in Presentation at ASH 2018 Interim results suggest rivo-cel outcomes were comparable to a control study…
Bellicum Pharmaceuticals, Inc. Bellicum Announces Interim Results Showing Rimiducid Controlled GvHD in Patients Treated with Rivo-cel Following a Stem Cell Transplant Experience to date in clinical study shows high clinical…
Poseida Therapeutics FDA Grants Poseida’s P-BCMA-101 Regenerative Medicine Advanced Therapy (RMAT) Status for Treatment of Multiple Myeloma November 19, 2018
AsclepiX Therapeutics AsclepiX Therapeutics Raises $5M in New Funding Financing will advance clinical development of the Company’s lead product AXT107 November 15, 2018